P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)

• M. Diez-Campelo,
• A. Yucel,
• R. Goyal,
• R. C. Parikh,
• S. Dhuliawala,
• M. Jimenez,
• M. Sluga-O’Callaghan,
• C. Hughes,
• D. Tang,
• U. Germing

Affiliations

M. Diez-Campelo

1 Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

A. Yucel

2 Bristol Myers Squibb, Princeton, NJ

R. Goyal

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

R. C. Parikh

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

S. Dhuliawala

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

M. Jimenez

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

M. Sluga-O’Callaghan

4 RTI Health Solutions, Lyon, France

C. Hughes

5 Bristol Myers Squibb, Summit, NJ, United States of America

D. Tang

2 Bristol Myers Squibb, Princeton, NJ

U. Germing

6 University Hospital of Dusseldorf, Dusseldorf, Germany